Multiple Sclerosis - Diet and MS: Food and Fellowship
Links shared publicly online about this topic.
- 1,262total visits
Multiple Sclerosis - Diet and MS: Food and Fellowship
View full resource at healthcentral.com
Tags: Multiple Sclerosis, Diet and Nutrition
Most Recently Shared on April 5, 2010 at 6:26 pm By:
Taking MS on the Road: Food and Fellowhsip - Last Thursday I had a wonderful opportunity to meet some ladies (livin... http://ow.ly/16Z975
FDA Approves 1st Oral Medication for MS - Yahoo! News
news.yahoo.com — “Read 'FDA Approves 1st Oral Medication for MS' on Yahoo! News. WEDNESDAY, Sept. 22 (HealthDay News) -- The U.S. Food and Drug Administration on Wednesday approved the first oral drug to treat multiple sclerosis, the nervous system disorder that has traditionally been treated with injectable drugs.” View full resource at news.yahoo.com
Most Recently Shared on July 11, 2011 at 11:07 pm By:
FDA Approves 1st Oral Medication for MS: WEDNESDAY, Sept. 22 (HealthDay News) -- The U.S. Food and Drug Adminis... http://yhoo.it/onYpzj
Potential impact of cinnamon on multiple sclerosis studied
medicalxpress.com — “A neurological scientist at Rush University Medical Center has received a grant from the National Institutes of Health (NIH) to evaluate whether cinnamon, a common food spice and flavoring material, may stop the destructive process of multiple sclerosis (MS).” View full resource at medicalxpress.com
Most Recently Shared on June 22, 2011 at 4:39 pm By:
PhysOrg Health News Health News
Potential impact of cinnamon on multiple sclerosis studied http://tw.medicalxpress.com/227965094
Be Supplement Savvy
healthyfellow.com — “Be Supplement Savvy” View full resource at healthyfellow.com
Most Recently Shared on April 16, 2011 at 2:16 am By:
The Latest News & Research About the Nutritional Supplements: Astaxanthin, Cinnamon & Saffron http://j.mp/eBd9Sg - #health
University of Pennsylvania Researcher Awarded $240,000 for Multiple Sclerosis Research
newswise.com — “A Pennsylvania researcher will receive $240,000 to continue his study of impaired vision and fatigue in patients with multiple sclerosis (MS), through the National Multiple Sclerosis Society and American Academy of Neurology Foundation Clinician-Scientist Development Award. Salim Chahin, MD, a postdoctoral fellow at the University of Pennsylvania in Philadelphia, PA, was awarded the fellowship for his work investigating the relationship between a loss of cells in the retina and impaired vision a” View full resource at newswise.com
Most Recently Shared on April 14, 2011 at 2:39 am By:
University of Pennsylvania Researcher Awarded $240,000 for Multiple Sclerosis Research: A Pennsylvania researche... http://bit.ly/gnz8mJ
University of Pennsylvania Researcher Awarded $240,000 for Multiple Sclerosis Research
newswise.com — “A Pennsylvania researcher will receive $240,000 to continue his study of impaired vision and fatigue in patients with multiple sclerosis (MS), through the National Multiple Sclerosis Society and American Academy of Neurology Foundation Clinician-Scientist Development Award. Salim Chahin, MD, a postdoctoral fellow at the University of Pennsylvania in Philadelphia, PA, was awarded the fellowship for his work investigating the relationship between a loss of cells in the retina and impaired vision a” View full resource at newswise.com
Most Recently Shared on April 13, 2011 at 10:54 pm By:
#health news: University of Pennsylvania Researcher Awarded $240,000 for Multiple Sclerosis Research: A Pennsylv... http://bit.ly/h6l2nc
EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis
news-medical.net — “EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).” View full resource at news-medical.net
Most Recently Shared on March 2, 2011 at 10:55 am By:
News-Medical.Net Health News and Oncology
Oncology News: EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis:... http://bit.ly/eokKUi
Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging
physorg.com — “(PhysOrg.com) -- A first-line treatment for relapsing forms of multiple sclerosis (MS) was approved in September 2010 by the US Food and Drug Administration: FTY720 (fingolimod, Gilenya), which acts as a sphingosine 1-phosphate (S1P) receptor modulator.” View full resource at physorg.com
Most Recently Shared on February 4, 2011 at 7:03 pm By:
Imaging against multiple sclerosis: Iodinated radiotracer candidate for PET and SPECT imaging: (PhysOrg.com) -- ... http://bit.ly/ecouE5
Scripps Research Study Reveals Unexpected Mechanism Of New Multiple Sclerosis Treatment
medicalnewstoday.com — “In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition calle” View full resource at medicalnewstoday.com
Most Recently Shared on December 22, 2010 at 1:05 pm By:
MNT Neurology News Neurology and Health News
Scripps Research Study Reveals Unexpected Mechanism Of New Multiple Sclerosis Treatment http://mnt.to/3PmF #neurology
Gilenya offers more benefits for MS therapy than previously realized
news-medical.net — “In September, patients suffering from multiple sclerosis (MS) received the welcome news that the U.S. Food and Drug Administration (FDA) had approved a promising new drug for their condition called Gilenya. Now, a team from The Scripps Research Institute has discovered that this drug's success may involve an unexpected biological mechanism acting within the central nervous system (CNS). This difference may mean that Gilenya offers even more benefits than previously realized and would represent t” View full resource at news-medical.net
Most Recently Shared on December 21, 2010 at 11:29 am By:
Gilenya offers more benefits for MS therapy than previously realized: In September, patients suffering from mult... http://bit.ly/hnV5Vj
Home Page
mindingmymitochondria.com — “Home Page for the book Minding My Mitochondria and Food and Brain Health. It is a book about the use of intensive nutrition to treat secondary progressive multiple sclerosis, neurological and psychological problems.” View full resource at mindingmymitochondria.com
Most Recently Shared on December 13, 2010 at 2:48 pm By:
Sara Stein MD Doctor, Psychiatrist, and Physician
#MS #ifmfnc - Food is Medicine! Terry Wahls MD on her remarkable recovery from secondary progressive MS: "When I... http://fb.me/M8ugcIPR
Biogen Idec Awards Clinical Fellowship Program Grants To Support Education And Research For The Treatment Of Multiple Sclerosis
medicalnewstoday.com — “As part of its commitment to furthering the quality of education in the field of multiple sclerosis (MS), Biogen Idec (NASDAQ: BIIB) is proud to announce that it provided grants to twelve prestigi” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2010 at 7:05 pm By:
Biogen Idec Awards Clinical Fellowship Program Grants To Support Education And Research For The Treatment Of Multiple ... http://mnt.to/3NPz
FDA extends review period of Cladribine Tablets for MS therapy
news-medical.net — “EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has extended its review period for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS) by three months to February 28, 2011.” View full resource at news-medical.net
Most Recently Shared on November 26, 2010 at 8:49 am By:
News-Medical.Net Health News and Oncology
Oncology News: FDA extends review period of Cladribine Tablets for MS therapy: EMD Serono, an affiliate of Merck... http://bit.ly/dXkQQg
FDA Approves First Oral Drug To Reduce MS Relapses
medicalnewstoday.com — “The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).” View full resource at medicalnewstoday.com
Most Recently Shared on September 24, 2010 at 11:05 pm By:
MNT Drug Approvals Health News
FDA Approves First Oral Drug To Reduce MS Relapses http://mnt.to/3Khy #regulatory
FDA Approves First Oral Drug To Reduce MS Relapses
medicalnewstoday.com — “The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).” View full resource at medicalnewstoday.com
Most Recently Shared on September 23, 2010 at 2:37 pm By:
FDA Approves First Oral Drug To Reduce MS Relapses: The U.S. Food and Drug Administration has approved Gilenya cap... http://mnt.to/f/3Kdv
Multiple Sclerosis Drug Gilenya (Fingolimod) Approved By FDA - QualityPoint Technologies
qualitypointtech.net — “Gilenya (fingolimod) 0.5 mg daily for the treatment of relapsing forms of multiple sclerosis has been approved by the Food and Drug Administration. Swiss pharmaceutical company, Novartis, says that Gilenya is the first oral medication indicated for relapsing forms of multiple sclerosis (MS) in the United States - it reduces the frequency of MS flare-up, as well as helping slow down the build-up of some of the physical problems associated with MS. Clinical trials involving 2,600 patients demonstr” View full resource at qualitypointtech.net
Most Recently Shared on September 22, 2010 at 7:12 pm By:
Multiple Sclerosis Drug Gilenya (Fingolimod) Approved By FDA: Gilenya (fingolimod) 0.5 mg daily for the treatment ... http://bit.ly/dxL7QD
Advertisement
